Format

Send to

Choose Destination
J Pediatr Gastroenterol Nutr. 2009 Jan;48(1):48-54. doi: 10.1097/MPG.0b013e31816533d3.

Fecal calprotectin and lactoferrin as noninvasive markers of pediatric inflammatory bowel disease.

Author information

1
Department of Paediatric Gastroenterology, University Hospital of Wales, Cardiff, UK. arpijois@yahoo.co.uk

Abstract

OBJECTIVE:

To evaluate whether fecal calprotectin (FC) and fecal lactoferrin (FL) can be used as noninvasive markers in children and young people (4-17 years) with active inflammatory bowel disease (IBD).

PATIENTS AND METHODS:

Stool samples were collected from 3 groups of children: those with active IBD, control individuals with other gastrointestinal (GI) diseases (GI control) and control individuals with no GI disease (non-GI control). The number of patients for the FC assay was as follows: IBD = 26, GI control = 30, non-GI control = 25. The number of patients for the FL assay was as follows: IBD = 24, GI control = 26, non-GI = 24. FC and FL were measured by use of enzyme-linked immunoassays.

RESULTS:

The median concentrations of FC and FL in isolation, and their interaction, were significantly higher in the IBD group than in the GI and non-GI control groups (P < 0.001). Although the area under the curve, sensitivity, and specificity for FC, FL, and FC x FL interaction were significantly better than chance, FL consistently had the lowest area under the curve, and FC x FL consistently had the highest area under the curve.

CONCLUSIONS:

FC and FL are both significantly elevated in children with IBD, and the interaction of these 2 biomarkers may produce a better initial diagnostic test compared with their use in isolation.

PMID:
19172123
DOI:
10.1097/MPG.0b013e31816533d3
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center